About us
Curileum is a discovery stage company in London targeting defective mucosal stem cells that underpin serious gastrointestinal (GI) diseases and disorders with major GI complications.
Curileum is a discovery stage company in London targeting defective mucosal stem cells that underpin serious gastrointestinal (GI) diseases and disorders with major GI complications.
We are discovering novel targets and drugs to correct imbalances in cell number and composition of the mucosal barrier – eliminating precancerous cells and dampening chronic inflammation in IBD and obesity – rather than treating the consequences of disease development.
Jeff Moore
Founder & CEO
We discover and validate novel therapeutic targets by comparing the in vitro properties of stem cells from healthy and diseased intestinal tissues to reveal the triggers of cell production and new targets for intervention.
Degradation of the single cell lining of the intestine leads to disease. Bacterial toxins permeate mucosal tissue and activate potent inflammatory responses.
Instead of treating disease symptoms in the $35bn gastrointestinal market, Curileum is targeting stem cells to correct imbalances in the numbers and functions of cells to restore intestinal health.
Harmful bacteria and chronic disease degrade the mucosal barrier
Disease
Diabetes and obesity
Chronic inflammation and ageing can select for defective stem cells
Disease
Inflammatory bowel disease
Cancer
Reduced pacemaker cells and chronic inflammation leads to slow motility
Disease
Diabetes and obesity
If you’re interested in finding out further details regarding our stem cell drug discovery and development work then get in contact with us.